Oncology Institute Beheer

Beheer criteriumcontroles 3/4

De CEO Oncology Institute is Dan Virnich, benoemd in Jun2023, heeft een ambtstermijn van 1.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 808.13K, bestaande uit 56.3% salaris en 43.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.77% van de aandelen van het bedrijf, ter waarde $ 171.44K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 3 jaar.

Belangrijke informatie

Dan Virnich

Algemeen directeur

US$808.1k

Totale compensatie

Percentage CEO-salaris	56.3%
Dienstverband CEO	1.4yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

Jul 19

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 05

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Mar 21

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

Mar 05

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Nov 10

The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit

Aug 09

Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings

May 18

Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth

Mar 16

Analyse CEO-vergoeding

Hoe is Dan Virnich's beloning veranderd ten opzichte van Oncology Institute's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$59m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$808k	US$455k	-US$68m
Sep 30 2023	n/a	n/a	-US$61m
Jun 30 2023	n/a	n/a	-US$50m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$3m	US$446k	US$68k
Sep 30 2022	n/a	n/a	-US$1m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	US$6m
Dec 31 2021	US$8m	US$263k	-US$11m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$419k	US$214k	-US$14m

Compensatie versus markt: De totale vergoeding ($USD 808.13K ) Dan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 651.15K ).

Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dan Virnich (45 yo)

1.4yrs

Tenure

US$808,129

Compensatie

Dr. Daniel Virnich, also known as Dan, M.D., M.B.A., FACHE, is Chief Executive Officer of The Oncology Institute Inc. since June 2023 and serves as its Executive Director since June 13, 2024. He served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Barasch	Chairman of the Board	5yrs	US$162.40k	0.34% $ 75.9k
Daniel Virnich	CEO & Executive Director	1.4yrs	US$808.13k	0.77% $ 171.4k
Yale Podnos	Chief Medical Officer	3yrs	US$591.28k	0.056% $ 12.5k
Rob Carter	Chief Financial Officer	less than a year	geen gegevens	0.0062% $ 1.4k
Jeremy Castle	Chief Operations Officer	1.2yrs	geen gegevens	geen gegevens
Mark Hueppelsheuser	General Counsel	9.8yrs	geen gegevens	geen gegevens
Laura Szitar	Chief People Officer	no data	geen gegevens	geen gegevens
Jordan McInerney	Chief Development Officer	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TOI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Barasch	Chairman of the Board	5yrs	US$162.40k	0.34% $ 75.9k
Daniel Virnich	CEO & Executive Director	less than a year	US$808.13k	0.77% $ 171.4k
Mark Pacala	Independent Director	2.2yrs	US$160.32k	0.12% $ 26.1k
Bradford Hively	Vice Chairman	3yrs	US$1.34m	0.55% $ 123.3k
Anne McGeorge	Independent Director	3yrs	US$188.81k	0.095% $ 21.0k
Gabe Ling	Director	2.2yrs	US$143.70k	0.038% $ 8.6k
Maeve O'Meara	Independent Director	3yrs	US$171.89k	0.078% $ 17.4k
Mohit Kaushal	Independent Director	4.7yrs	US$180.22k	0.12% $ 26.2k
Karen Johnson	Independent Director	3yrs	US$177.53k	0.084% $ 18.6k

3.0yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TOI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Oncology Institute Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

The Oncology Institute Announces CFO Changes

The Oncology Institute, Inc., Annual General Meeting, Jun 13, 2024

The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer

Key Executive recently bought US$127k worth of stock

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

Recent updates

The Oncology Institute, Inc. to Report Q3, 2024 Results on Nov 13, 2024

The Oncology Institute Announces CFO Changes

New major risk - Financial data availability

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.19 loss in 2Q 2023)

The Oncology Institute, Inc. Updates Earnings Guidance for the Full Year 2024

New minor risk - Shareholder dilution

The Oncology Institute, Inc. to Report Q2, 2024 Results on Aug 13, 2024

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

The Oncology Institute, Inc. Receives A Written Notice from the Nasdaq Stock Market LLC

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.33 loss in 1Q 2023)

The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Year 2024

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Oncology Institute, Inc., Annual General Meeting, Jun 13, 2024

The Oncology Institute, Inc. to Report Q1, 2024 Results on May 14, 2024

New minor risk - Market cap size

The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer

Full year 2023 earnings released: US$0.92 loss per share (vs US$0.001 profit in FY 2022)

The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

The Oncology Institute, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

New major risk - Share price stability

Key Executive recently bought US$127k worth of stock

New minor risk - Market cap size

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

New major risk - Revenue and earnings growth

the Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.03 loss in 3Q 2022)

The Oncology Institute, Inc. to Report Q3, 2023 Results on Nov 08, 2023

The Oncology Institute, Inc. Names Jeremy Castle as Chief Operations Officer

New major risk - Revenue and earnings growth

The Oncology Institute Regains Compliance with Nasdaq Listing Requirements

The Oncology Institute, Inc. Appoints Jeremy N. Castle as Chief Operations Officer

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for 2,000,000 shares, for $2 million.

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.062 loss in 2Q 2022)

The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Full Year 2023

New minor risk - Shareholder dilution

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for 5,000,000 shares, for $3.75 million.

The Oncology Institute, Inc. Appoints Brad Hively as Vice Chair of the Board

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Southland Radiation Oncology Network.

the Oncology Institute, Inc. Announces Departure of Matthew Miller, M.D. as Chief Operating Officer Effective June 16, 2023

The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.41 loss per share (vs US$0.21 profit in 1Q 2022)

The Oncology Institute, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2023

The Oncology Institute, Inc. Patient to Be Treated with Promising Therapy for Metastatic Ovarian Cancer

Full year 2022 earnings released: EPS: US$0.023 (vs US$0.17 loss in FY 2021)

The Oncology Institute, Inc. to Report Q4, 2022 Results on Mar 09, 2023

Chief Operating Officer recently bought US$70k worth of stock

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Practice of Dr. Labib Hashimi.

President exercised options to buy US$382k worth of stock.

The Oncology Institute, Inc. Announces Diona Simoneit to Resign as Chief Accounting Officer and Principal Accounting Officer

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired The South Miami Clinic.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

The Oncology Institute, Inc. Revises Earnings Guidance for the Year 2022

Independent Director notifies of intention to sell stock

The Oncology Institute, Inc. to Report Q3, 2022 Results on Nov 09, 2022

the Oncology Institute, Inc. Announces Executive Appointments

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired BROWARD ONCOLOGY ASSOCIATES.

The Oncology Institute Enrolls Nation's First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib

The Oncology Institute, Inc. Appoints Two New Board Members

Second quarter 2022 earnings released: US$0.062 loss per share (vs US$0.049 profit in 2Q 2021)

The Oncology Institute, Inc. Provides Revenue Guidance for 2022

The Oncology Institute, Inc. announced that it has received $110 million in funding

The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Practice of Dr. Nutan Parikh.